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Antiangiogenic Activity of Semisynthetic
Biotechnological Heparins
Low-Molecular-Weight–Sulfated Escherichia coli K5 Polysaccharide
Derivatives as Fibroblast Growth Factor Antagonists
Marco Presta, Pasqua Oreste, Giorgio Zoppetti, Mirella Belleri, Elena Tanghetti, Daria Leali,
Chiara Urbinati, Antonella Bugatti, Roberto Ronca, Stefania Nicoli, Emanuela Moroni, Helena Stabile,
Maura Camozzi, German Andre´s Hernandez, Stefania Mitola, Patrizia Dell’Era,
Marco Rusnati, Domenico Ribatti
Objective—Low-molecular-weight heparin (LMWH) exerts antitumor activity in clinical trials. The K5 polysaccharide
from Escherichia coli has the same structure as the heparin precursor. Chemical and enzymatic modifications of K5
polysaccharide lead to the production of biotechnological heparin-like compounds. We investigated the fibroblast
growth factor-2 (FGF2) antagonist and antiangiogenic activity of a series of LMW N,O-sulfated K5 derivatives.
Methods and Results—Surface plasmon resonance analysis showed that LMW-K5 derivatives bind FGF2, thus inhibiting
its interaction with heparin immobilized to a BIAcore sensor chip. Interaction of FGF2 with tyrosine-kinase receptors
(FGFRs), heparan sulfate proteoglycans (HSPGs), and v3 integrin is required for biological response in endothelial
cells. Similar to LMWH, LMW-K5 derivatives abrogate the formation of HSPG/FGF2/FGFR ternary complexes by
preventing FGF2-mediated attachment of FGFR1-overexpressing cells to HSPG-bearing cells and inhibit FGF2-
mediated endothelial cell proliferation. However, LMW-K5 derivatives, but not LMWH, also inhibit FGF2/v3 integrin
interaction and consequent FGF2-mediated endothelial cell sprouting in vitro and angiogenesis in vivo in the chick
embryo chorioallantoic membrane.
Conclusions—LMW N,O-sulfated K5 derivatives affect both HSPG/FGF2/FGFR and FGF2/v3 interactions and are
endowed with FGF2 antagonist and antiangiogenic activity. These compounds may provide the basis for the design of
novel LMW heparin-like angiostatic compounds. (Arterioscler Thromb Vasc Biol. 2005;25:71-76.)
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Heparin is a natural sulfated glycosaminoglycan (GAG)used as anticoagulant and antithrombotic drug.1 Heparin
is heterogeneous in size: unfractionated heparin (UFH) shows
an average molecular weight (MW) of 13 000 to 15 000 with
chains ranging from 5000 to 30 000. Heparin structure is
largely accounted for by regular trisulfated disaccharide
sequences made of alternating -1,4-linked residues of 2-O-
sulfated L-iduronic acid (IdoA) and N,6-disulfated
D-glucosamine (GlcN). These sequences are occasionally
interrupted by nonsulfated uronic acids and undersulfated
hexosamines,1 including 3-O–sulfated GlcNs present in the
antithrombin III–binding pentasaccharidic sequence relevant
for anticoagulant activity.2
Heparin binds to a variety of biologically active polypep-
tides.3 This capacity may be exploited to design heparin-
derived drugs for pharmacological interventions in a variety
of pathologic conditions besides coagulation and thrombosis,
including neoplasia. Actually, heparins show antitumor ac-
tivity in clinical trials4–6 without affecting the incidence of
thrombotic and bleeding complications, thus suggesting a
direct effect of heparins on cancer progression. Indeed,
heparins may inhibit malignant growth by different mecha-
nisms,6,7 including the suppression of tumor neovasculariza-
tion after interaction with angiogenic growth factors (re-
viewed in Presta et al8).
Fibroblast growth factor-2 (FGF2) is a major heparin-
binding angiogenic growth factor and a possible target for
antiangiogenic therapies.9 FGF2 exerts its activity on endo-
thelial cells by interacting with tyrosine-kinase receptors
(FGFRs)10 and heparan sulfate proteoglycans (HSPGs),11
thus forming HSPG/FGF2/FGFR ternary complexes.12 Hep-
arin competes with HSPGs and FGFRs for the binding to
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FGF2.13 Therefore, synthetic molecules and chemically mod-
ified heparins able to interfere with HSPG/FGF2/FGFR
interaction may act as angiogenesis inhibitors (reviewed in
Presta et al8). Also, FGF2 binds to endothelial v3 integrin,
and this interaction is required for biological response.14,15
Accordingly, FGF2/v3 integrin interaction antagonists are
endowed with antiangiogenic activity in vitro and in vivo.16
The capsular K5 polysaccharide from Escherichia coli has
the same structure [3 4)--D-GlcA-(1 3 4)--D-GlcNAc-
1(1 3]n as the heparin precursor N-acetyl heparosan17 in
which GlcA is glucuronic acid and GlcNAc is N-acetyl-
glucosamine. Chemical and enzymatic modifications of the
K5 polysaccharide lead to the synthesis of heparin-like
compounds18 endowed with different biological properties,
including anticoagulant/antithrombotic,19,20 antineoplastic,21
and anti-AIDS22 activities. Recently, we demonstrated that a
highly N,O–sulfated K5 derivative [K5-N,OS(H)] binds
FGF2 with high affinity and exerts a potent antiangiogenic
activity.23 Thus, K5-N,OS(H) may provide the basis for the
design of novel angiostatic compounds with therapeutic
implications in different angiogenesis-dependent diseases,
including cancer.
Low-molecular-weight heparins (LMWHs) are obtained by
chemical or enzymatic depolymerization of UFH. LMWH
has favorable pharmacokinetics compared with conventional
heparin.24,25 Relevant to the use of heparins in cancer therapy,
LMWH prolongs disease-free survival time and reduces
death rate in cancer patients.6 In this study, we synthesized a
series of LMW derivatives of K5-N,OS(H) that were assessed
for their FGF2 antagonist activity in vitro and angiostatic
capacity in vivo.
Methods
Materials
Recombinant FGF2 was from Pharmacia-Upjohn (Milan, Italy).
UFH (average MW13 700; sulfate/carboxyl ratio [SO3/
COO]2.14) was obtained from unfractionated beef mucosa so-
dium heparin (Laboratori Derivati Organici, Milan, Italy). LMWH
(average MW5000; SO3/COO2.13) was provided by C. Pisano
(Sigma-Tau, Pomezia, Italy). K5 polysaccharide (average
MW30 000) was prepared as described.23 Cyclo(-Arg-Gly-Asp-D-
Phe-Val) peptide [c(RGDfV)] and cyclo(-Arg-Ala-Asp-D-Phe-Val)
peptide [c(RADfV)] were from Bachem AG.
LMW-K5 Derivatives
Derivatives were generated by nitrous acid depolymerization and
subsequent reduction from a single batch of K5-N,OS(H)23 (for
details, please see the online Methods, available at http://atvb.
ahajournals.org.). 13C-NMR spectrum analysis, SO3/COO analy-
sis, and MW determinations of the different samples were performed
as described.23
BIAcore Binding Assay
Biotinilated UFH was immobilized (6.0 fmol/mm2) to a streptavidin-
activated sensor chip (BIAcore Inc, Piscataway, NJ). Increasing
concentrations of FGF2 in 10 mmol/L HEPES, 150 mmol/L NaCl,
3.4 mmol/L EDTA, 0.005% surfactant P20 (pH 7.4), were then
injected over the heparin-coated surface for 4 minutes and washed
until dissociation was observed. The signal was expressed as
resonance units. Also, FGF2 (160 nmol/L) was injected over the
heparin-coated sensor chip in the presence of increasing GAG
concentrations. A streptavidin-activated sensor chip was used for
blank subtraction.
FGF2-Mediated Cell–Cell Adhesion Assay
Chinese hamster ovary (CHO)-K1 cells were seeded at 52 000 cells
per cm2 in 24-well plates. After 24 hours, cell monolayers were fixed
with 3% glutaraldehyde in PBS. Then, A745 CHO flg-1A cells,
generated by transfection of GAG-deficient A745 CHO cells26 with
the IIIc variant of murine FGFR1 cDNA,27 were added at 52 000
cells per cm2 to CHO-K1 monolayers in serum-free medium plus
10 mmol/L EDTA with no addition or with 30 ng/mL FGF2 in the
presence of increasing concentrations of the different GAGs. After 2
hours at 37°C, cells bound to the monolayer were counted under an
inverted microscope.23
Cell Proliferation Assay
Bovine endothelial GM7373 cells (Human Genetic Mutual Cell
Repository, Camden, NJ) were seeded at 70 000 cells per cm2 in
24-well plates. After overnight incubation in Eagle’s minimal essen-
tial medium containing 10% FCS, cells were incubated in medium
containing 0.4% FCS and 10 ng/mL FGF2. After 8 hours, increasing
concentrations of GAGs were added to cell cultures without chang-
ing the medium. Sixteen hours thereafter, cells were trypsinized and
counted.23
Fibrin Gel Sprouting Assays
FGF2-transfected murine endothelial FGF2-T-MAE cell aggre-
gates28 were prepared on agarose-coated plates and seeded within
fibrin gel.23 Then, culture medium with or without K5 derivatives
(100 g/mL) or cyclic pentapeptides (60 mol/L) was added.
Formation of radially growing cell sprouts was quantified after 24
hours by image analysis of the digitized images using the Image-Pro
Plus software (Media Cybernetics). Freshly prepared rat aorta rings29
were cultured in fibrin gel for 7 days in the presence of the different
antagonists. Rings were examined daily and neovessels counted
under an inverted microscope.
Cell Adhesion Assay
Polystyrene nontissue culture 96-well plates were coated with 20
g/mL FGF2, vitronectin, or fibronectin as described.14 Next,
50 000 GM7373 cells were seeded in the absence or presence of the
antagonist. After 2 hours at 37°C, adherent cells were quantified by
methylene blue/Azur II staining.14
Chick Embryo Chorioallantoic Membrane Assay
At day 8 of incubation, sterilized gelatin sponges (1 mm3; Gelfoam,
Upjohn Co) adsorbed with the K5-derivative dissolved in 3 L of
PBS (50 g/embryo) were implanted on the top of growing cho-
rioallantoic membranes (CAMs).23 Sponges containing vehicle alone
were used as negative controls. CAMs were examined under a
stereomicroscope until day 12, and blood vessels around the sponges
were counted (10 eggs per group).
Results
Production of LMW-K5 Derivatives
K5 derivatives with reduced size were prepared by controlled
chemical depolymerization of K5-N,OS(H) (SO3/
COO3.87; average MW of 20 700). Three LMW com-
pounds [LMW-K5(A), LMW-K5(B), and LMW-K5(C) with
MW equal to 6000, 5000, and 4200, respectively] and 1
derivative with an intermediate MW of 11 000 (IMW-K5)
were obtained. As for K5-N,OS(H),23 the compounds carry 1
N-sulfated group and 1 6-O–sulfated group in all GlcN
residues, with 70% of their sequence being represented by
GlcA2,3SO3-GlcNSO3,6SO3 disaccharide units (Figure I,
available online at http://atvb.ahajournals.org).
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Binding of LMW-K5 Derivatives to FGF2
LMW-K5 derivatives were evaluated for the capacity to interact
with FGF2 by preventing its binding to biotinilated heparin
immobilized onto a streptavidin-activated BIAcore sensor chip.
FGF2 binds to the heparin-coated sensor chip, but not to the
streptavidin-activated sensor chip, in a dose-dependent manner
(Figure II, available online at http://atvb.ahajournals.org). An
association rate constant equal to 9.0103 M1 s1 and a
dissociation rate constant equal to 3.8104 s1 characterize the
interaction that occurs with high affinity (Kd42.5 nmol/L),
consistent with previous determinations.30,31
On this basis, increasing concentrations of LMW-K5
derivatives or UFH were preincubated with FGF2 and then
injected onto the heparin-coated sensor chip. All the com-
pounds caused a dose-dependent inhibition of FGF2/heparin
interaction (Figure 1). LMW-K5(A), LMW-K5(B), and
LMW-K5(C) showed a similar potency (ID50100 to 120
nmol/L), 4 to 5 lower than that observed for K5-N,OS(H)
and IMW-K5. These differences were, however, abolished
when the concentration of the different compounds was
expressed on a weight basis (ID50 values ranging from 0.3
g/mL to 0.6 g/mL). When compared with K5 derivatives,
UFH (MW of 13 700) appeared to be a more active compet-
itor (ID506.0 nmol/L, corresponding to 0.08 g/mL). Fi-
nally, a LMWH preparation (MW of 5000) inhibited the
binding of FGF2 to immobilized heparin with a similar
potency (ID5020 nmol/L, corresponding to 0.1 g/mL;
Figure 1). No effect was instead exerted by unmodified K5
(not shown).
Effect of LMW-K5 Derivatives on
HSPG/FGF2/FGFR Ternary Complex
FGF2 mediates cell–cell attachment by linking FGFRs and
HSPGs on neighboring cells through the formation of HSPG/
FGF2/FGFR ternary complexes.32 Indeed, HSPG-deficient
FGFR1-transfected A745-CHO flg-1A cells adhere to a
monolayer of HSPG-bearing CHO-K1 cells when incubated
in the presence of 30 ng/mL FGF2 but not in the absence of
the growth factor.27 K5-N,OS(H) inhibits FGF2-mediated
cell–cell attachment in this model.23
When tested under the same experimental conditions, all
the LMW-K5 compounds and IMW-K5 hamper the forma-
tion of the HSPG/FGF2/FGFR ternary complex with an
activity equal to that shown by the parent compound K5-
N,OS(H) and LMWH (ID500.3 g/mL) and only slightly
less potent than that exerted by UFH (ID500.1 g/mL).
Unmodified K5 was ineffective (Figure 2A).
Effect of LMW-K5 Derivatives on Endothelial Cell
Proliferation and Sprouting
To evaluate a possible angiosuppressive activity of LMW-K5
derivatives, we evaluated their capacity to affect FGF2-
Figure 1. Surface plasmon resonance analysis of LMW-K5
derivative/FGF2 interaction. FGF2 (160 nmol/L) was injected
over a heparin-coated BIAcore sensor chip in the presence of
increasing concentrations of the different GAGs. The response
was recorded at the end of injection and plotted as a function
of the GAG concentration.
Figure 2. Effect of LMW-K5 derivatives on FGF2-mediated cell–
cell adhesion and endothelial cell proliferation. A, HSPG-
deficient FGFR1 transfectants were added to CHO monolayers
in the presence of 30 ng/mL FGF2 and increasing concentra-
tions of the different GAGs. After 2 hours at 37°C, adherent cells
were counted. B, The different GAGs were tested for the capac-
ity to inhibit FGF2-mediated proliferation in GM7373 cells. Data
are expressed as percentage of the proliferation measured in
the absence of any competitor. In both A and B, experiments
were performed in triplicate and repeated 3 with similar
results.
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mediated cell proliferation in bovine endothelial GM7373
cells. Similar to heparin and LMWH, LMW-K5 derivatives
and IMW-K5 inhibit endothelial cell proliferation (ID501 to
3 g/mL). No inhibition was instead exerted by unmodified
K5 (Figure 2B).
The capacity of K5 derivatives to affect angiogenesis was
investigated further by an in vitro sprout formation assay. In
this assay, FGF2-transfected endothelial FGF2-T-MAE cell
aggregates are embedded into a fibrin gel in which they form
solid cell sprouts after 1 to 2 days in culture.33 As shown in
Figure 3A (see also Figure III, available online at http://
atvb.ahajournals.org), K5 derivatives exert a significant in-
hibitory effect on FGF2-T-MAE cell sprouting, whereas
unmodified K5, UFH, and LMWH are ineffective. Also,
endothelial cell sprouting was suppressed by the v3 integrin
antagonist cyclic pentapeptide c(RGDfV)34 but not by the
control peptide c(RADfV; Figure 3A).
Accordingly, LMW-K5(A) and c(RGDfV), but not
LMWH and c(RADfV), inhibit endothelial cell sprouting in
an ex vivo assay in which new capillary-like structures
originate spontaneously from the endothelium of fibrin-
embedded rat aorta rings29 (Figure 3B and Figure III).
Effect of LMW-K5 Derivatives on FGF2/v3
Integrin Interaction
Integrins, including v3, play an important role in angiogen-
esis.35 Also, FGF2 binds v3, and this interaction is required
for endothelial cell response to the growth factor.14–16 The
capacity of K5 derivatives to inhibit endothelial cell sprouting
similar to the integrin antagonist c(RGDfV) prompted us to
assess the possibility that K5 derivatives may affect FGF2/
v3 interaction. Endothelial cells adhere and spread on
FGF2-coated plastic through FGF2/v3 interaction.14,15 Both
K5-N,OS(H) and LMW-K5(C) prevent GM7373 cell adhe-
sion to immobilized FGF2, whereas UFH and LMWH are
ineffective (Figure 4). Similar results were obtained with
LMW-K5(A) and the integrin antagonist c(RGDfV), whereas
control c(RADfV) was ineffective (data not shown). The
effect of K5 derivatives on FGF2/v3-mediated endothelial
cell adhesion was specific, because K5-N,OS(H) and LMW-
K5(C) did not inhibit cell adhesion to the prototypic integrin
ligands vitronectin and fibronectin.
Effect of LMW-K5 Derivatives on Chick Embryo
CAM Angiogenesis
Various FGF2 antagonists, including heparin-like compounds
and v3 antagonists, exert a significant antiangiogenic ac-
tivity in the chick embryo CAM.16,23,36,37 When delivered on
the top of the CAM through a gelatin sponge implant, all the
K5 derivatives inhibited blood vessel growth. This was
observed in 70% of the embryos treated with K5-N,OS(H), in
80% of those treated with LMW-K5(A) or LMW-K5(B), and
in 90% of the embryos treated with LMW-K5(C). Accord-
ingly, the number of blood vessels surrounding the implants
decreased rapidly during incubation with K5-N,OS(H) or
with the different LMW-K5 compounds compared with the
physiological increase in vascularization observed in vehicle-
treated embryos (Figure 5 and Figure III). In agreement with
previous observations, unmodified K5 and heparin did not
affect CAM neovascularization.23,36,37
Discussion
Here, a series of LMW-K5 compounds (MW ranging from
6000 to 4200) obtained by controlled chemical depolymer-
Figure 3. Effect of LMW-K5 derivatives on endothelial cell
sprouting. A, FGF2-T-MAE cell aggregates were seeded in fibrin
gel in the presence of the different GAGs (100 g/mL) or cyclic
peptides (60 mol/L). After 24 hours, sprouting was evaluated
by computerized image analysis. Data are the meanSEM of 3
experiments in triplicate. B, Rat aorta rings were embedded in
fibrin gel in the presence of vehicle or of LMW-K5(A), LMWH
(both at 100 g/mL), or cyclic peptides (60 mol/L). Neovessels
that sprout out of the rings were counted during the next 7
days. Data represent 4 rings per experimental condition. Similar
results were obtained in a second independent experiment.
Figure 4. Effect of LMW-K5 derivatives on FGF2/v3 interac-
tion. GM7373 cells were seeded on plastic coated with FGF2,
fibronectin (FN), or vitronectin (VN) in the absence or presence
of UFH, LMWH, K5-N,OS(H), or LMW-K5(C). Adherent cells
were counted after 2 hours.
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ization of a high MW N,O-sulfated K5 derivative23 exert a
potent FGF2 antagonist activity in vitro and show antiangio-
genic capacity in vivo. Thus, as few as 8 monosaccharide
units [as in LMW-K5(C)] are sufficient to confer to K5-
N,OS(H) derivatives a full angiostatic capacity.
The minimal FGF2-binding sequence in heparan sulfate is
a pentasaccharide that contains the disaccharide units
IdoA2SO3-GlcNSO3 or IdoA2SO3-GlcNSO3,6SO3.38
K5 derivatives can be chemically and enzymatically modified
to reproducible structures in which sulfated groups and
GlcA/IdoA residues are distributed along the GAG chain in a
statistically homogenous manner.18,39–41 Surface plasmon
resonance analysis demonstrates that free K5-N,OS(H),
IMW-K5, and all LMW-K5 derivatives (70% of their
sequence represented by GlcA2,3SO3-GlcNSO3,6SO3 dis-
accharide units) compete with immobilized heparin for the
binding to FGF2 with similar potency and only slightly less
efficiently than free UFH or LMWH when GAG chain
concentration was expressed on a weight basis. This is in
keeping with the hypothesis that more FGF2 molecules bind
to a single heparin chain and that the stoichiometry of
FGF2/heparin complexes depends on the size of the GAG. A
single UFH or LMWH chain binds 6 or 2 FGF2 molecules,
respectively, both heparin types giving a heparin mass of
2300 per FGF2-binding site.42 Similarly, it is possible to
hypothesize that LMW-K5 chains can bind 2 to 3 FGF2
molecules per complex and that longer IMW-K5 and K5-
N,OS(H) chains will bind a proportionally higher number of
growth factor molecules.
FGF2 interaction with nonsignaling HSPGs is required for
the binding to FGFRs. FGFR occupancy will then lead to
multiple biological responses in cultured endothelial cells and
eventually to in vivo neovascularization.11 Similar to K5-
N,OS(H) and IMW-K5, LMW-K5 derivatives abrogate
FGF2-mediated attachment of FGFR1-expressing cells to
neighboring HSPG-bearing cells, thus indicating their ability
to prevent the formation of the HSPG/FGF2/FGFR ternary
complex.23 Synthetic molecules and chemically modified
heparins that interfere with HSPG/FGF2/FGFR interaction
act as angiogenesis inhibitors (reviewed in Presta et al8).
Accordingly, K5-N,OS(H) derivatives suppress neovascular-
ization in the chick embryo CAM.
Similar to K5 derivatives, heparin binds FGF2 and pre-
vents HSPG/FGF2/FGFR interaction and FGF2-driven endo-
thelial cell proliferation in vitro. However, at variance with
K5 derivatives, heparin does not affect endothelial cell
sprouting in vitro and angiogenesis in vivo. This apparent
discrepancy may be explained by the observation that K5
derivatives, but not heparin, also prevent the interaction of
FGF2 with v3 integrin. v3 plays an important role in
angiogenesis,35 and FGF2/v3 interaction is required for
endothelial cell response to the growth factor.14–16 Also,
numerous observations point to an intimate cross-talk be-
tween integrin-mediated intracellular signaling and angio-
genic growth factor tyrosine kinase receptor activation.43
Accordingly, v3 represents a target for angiostatic com-
pounds.44 Thus, the capacity of K5 derivatives to interfere
with both HSPG/FGF2/FGFR and FGF2/v3 interactions
results in a potent angiostatic activity.
K5 derivatives do not inhibit integrin-mediated endothelial
cell adhesion to vitronectin (a prototypic v3 ligand) or
fibronectin (a prototypic 51 ligand), indicating that the
observed FGF2/v3 antagonist activity is because of the
capacity of these compounds to bind the growth factor rather
than the integrin molecule. The characterization of the struc-
tural requirements for the FGF2/v3 antagonist activity of
K5 derivatives deserves further investigation.
Both thrombotic and hemorrhagic complications have been
reported in cancer patients undergoing antiangiogenic therapy
(discussed in Daly et al45). The occurrence of these life-
threatening complications suggests that the use of antiangio-
genic compounds endowed with anticoagulant activity or in
association with anticoagulants should be approached with
caution. Relevant to this point, K5-N,OS(H) and its LMW
derivatives are endowed with negligible anticoagulant activ-
ity (P.O. and G. Z., unpublished data, 2003). LMW-K5
compounds may therefore provide the basis for the design of
novel LMW angiostatic compounds with therapeutic impli-
cations in angiogenesis-dependent diseases, including cancer.
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Figure I. Schematic structure of K5-N,OS(H) derivatives. 70% of the saccharide sequence in 
K5-N,OS(H) and its LMW derivatives is represented by GlcA2,3SO3--GlcNSO3-,6SO3- disaccharide 
units. 
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Figure II. Surface plasmon resonance analysis of FGF2/heparin interaction. A) FGF2 (260 
nmol/L) was injected over streptavidin-activated (dotted line) or heparin-coated (straight line) 
BIAcore sensorchips. The response (in RU) was recorded as a function of time. B) Sensogram 
overlay showing the binding of increasing amounts of FGF2 (1060, 530, 260, 160, and 50 nmol/L 
from top to bottom) to immobilized heparin. 
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Figure III. Effect of LMW-K5 derivatives on endothelial cell sprouting and angiogenesis. 
FGF2-T-MAE cell aggregates (A) or rat aortic rings (B) were seeded in fibrin gel in the presence of 
vehicle (a) or 100 µg/mL LMW-K5(A) (b). Endothelial sprouts were photographed under an 
inverted microscope after 24 hours (A) or 7 days (B). C) CAMs were treated with vehicle (a) or 50 
µg LMW-K5(A) (b) at day 8 of incubation and photographed at day 12. Note the inhibitory effect 
exerted on endothelial cell sprouting and angiogenesis by LMW-K5(A). Original magnifications: 
x40 (A); x100 (B); x20 (C). 
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Synthesis of LMW-K5 derivatives. 
Derivatives were generated by nitrous acid depolymerization and subsequent reduction from a 
single batch of K5-N,OS(H) [average MW = 20,700; SO3-/COO- = 3.87] 1. To this purpose, 20 mL 
aliquots of an ice-cooled water solution containing 100 mg of K5-N,OS(H) were added with 
different volumes (from 4.0 to 11.5 mL) of 0.2 % sodium nitrite in water to obtain compounds with 
different final MW. The pH was adjusted to 2.0 with HCl, samples were kept for 30 minutes at 4°C 
under gentle stirring, then the pH was brought to pH 7.0 with NaOH. Next, 5 mL of 0.5% sodium 
borohydride in water were added and samples maintained at room temperature for 4 hours. Then, 
the pH was brought to 5.0 with HCl and back to 7.0-7.2 with NaOH after 30 minutes. Samples were 
concentrated, precipitated twice with acetone, and dried in a vacuum oven. 13C-NMR spectrum 
analysis, SO3-/COO- analysis, and MW determinations of the different samples were performed as 
described 1. 
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